B!BBInstruments is focused on the development of flexible endoscopic instruments for improved minimally invasive biopsies.
B!BBInstruments develops novel award-winning diagnostic instruments under the brand name EndoDrill® for early detection of cancerous tumors.
B!BBInstruments operates in the global multibillion market of flexible endoscopic biopsy instruments, with the objective to offer single-use products for earlier and more accurate cancer diagnosis that outperforms current commercial instruments.
B!BBInstruments develops EndoDrill®, a patented portfolio of biopsy instruments to improve cancer diagnosis. Cancer is a leading cause of death worldwide and the number of new cancer cases is on the rise globally as a result of an ageing population and a growing exposure to risk factors. Hence the need for earlier diagnosis before the cancer has the chance to get too big or spread is of utmost importance.
The Company’s current product pipeline includes single-use instruments for various indications, including cancer diagnosis of the stomach, bowels, lungs, breast and prostate. EndoDrill® uses a patented drill function that enables deep tissue samples of suspected tumors.
The first commercially available product, EndoDrill® GI Upper, is designed to solve a specific clinical problem of diagnosis of deep tumors in the stomach.
EndoDrill® GI Upper
EndoDrill® GI Upper is used to take vertical samples of the suspected cancer tissue in the stomach using the novel drill function, making it possible to provide earlier and more accurate
diagnosis of deep cancerous tumors. These deep tumors are often difficult to diagnose with conventional biopsy instruments and instead usually more complex techniques are required, including surgery, for definitive diagnosis. An early and precise diagnosis can be crucial to optimize the treatment, save lives, as well as saving significant costs for the health care system.
EndoDrill® Upper GI has been clinically validated at the Skåne University Hospital in Lund, Sweden, and it has been proven that the new instrument plays a significant role in diagnosing deep cancer tumors. Already the EndoDrill® Upper GI has given diagnosis of different types of deep and elusive tumors in several patients, where previous attempts with conventional instruments failed.
A randomized clinical study has been published in Surgical Innovation 2016, A New Method for Endoscopic Sampling of Submucosal Tissue in the Gastrointestinal Tract: A Comparison of Biopsy Forceps and a New Drill Instrument*.
In the study patients with newly detected submucosal tumors were examined with EndoDrill® Upper GI and compared with conventional biopsy forceps. EndoDrill® GI Upper gave significantly larger biopsies and more submucosal tissue without any serious complications.
EndoDrill® product portfolio
The EndoDrill® product portfolio offers various drill-based instruments that provide deeper and more vertical biopsies compared to instruments available on the market. This leads to the ability to take samples from lesions and tumors that could previously only be viewed, but often inadequately sampled, during an endoscopic examination. Biopsies performed with EndoDrill® enable more accurate characterization of tissue and improved diagnosis. EndoDrill® minimizes the need for tumor sampling by more complicated methods including surgery.
The EndoDrill® instrument allows for sampling of deeper situated tumors, an increasingly common type of tumor, as well as provides information of tumor growth depth, which cannot be achieved with current instrumentation. This is valuable information for improved treatment and prognosis.
The EndoDrill® can reduce the number of more complicated procedures and enables more patient friendly sampling and reduced cost.
* Walther C et al, A New Method for Endoscopic Sampling of Submucosal Tissue in the Gastrointestinal Tract: A Comparison of the Biopsy Forceps and a New Drill Instrument. Surg Innov. 2016 Apr 27.